WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 201450
CAS#: 236095-24-2 (HCl)
Description: Camsirubicin, also known as GPX-150, MNPR-201, and CNDO1011, is a synthetic non-cardiotoxic analogue of the anthracycline antibiotic doxorubicin with potential antineoplastic activity. Anthracycline analogue GPX-150 intercalates DNA and impedes the activity of topoisomerase II, inducing single and double-stranded breaks in DNA; inhibiting DNA replication and/or repair, transcription, and protein synthesis; and activating tumor cell apoptosis.
MedKoo Cat#: 201450
Name: Camsirubicin HCl
CAS#: 236095-24-2 (HCl)
Chemical Formula: C27H33ClN2O9
Exact Mass:
Molecular Weight: 565.02
Elemental Analysis: C, 57.40; H, 5.89; Cl, 6.27; N, 4.96; O, 25.48
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Related CAS #: 236095-24-2 (HCl) 236095-29-7 236095-26-4 (free base)
Synonym: MNPR-201; MNPR 201; MNPR201; CNDO1011; CNDO-1011; CNDO 1011; GPX150; GPX 150; GPX-150; GPX150 HCl; GPX150 hydrochloride; Camsirubicin HCl; Camsirubicin hydrochloride
IUPAC/Chemical Name: (8R,10S)-10-(((2S,4S,5R,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,8,11-trihydroxy-8-(2-hydroxyethyl)-12-imino-1-methoxy-7,8,9,10-tetrahydrotetracen-5(12H)-one hydrchloride
InChi Key: QVPRMGHPBJJSRU-KMIOROQSSA-N
InChi Code: InChI=1S/C27H32N2O9.ClH/c1-11-23(31)14(28)8-17(37-11)38-16-10-27(35,6-7-30)9-13-19(16)26(34)20-21(25(13)33)24(32)12-4-3-5-15(36-2)18(12)22(20)29;/h3-5,11,14,16-17,23,29-31,33-35H,6-10,28H2,1-2H3;1H/t11-,14-,16-,17+,23-,27-;/m0./s1
SMILES Code: O=C1C2=C(O)C(C[C@](CCO)(O)C[C@@H]3O[C@@H]4C[C@H](N)[C@@H](O)[C@H](C)O4)=C3C(O)=C2C(C5=C1C=CC=C5OC)=N.[H]Cl
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not soluble in water.
Shelf Life: >5 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 565.02 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1. Zhang; Xini (Hoover, AL), Olson; Richard D. (Nampa, ID) 5-imino-13-deoxy anthracycline derivatives, their uses, and processes for preparing them, United States Patent 5942605.
As of August 2010, GPX-150 is under Phase I clinical trials sponsored by Coronado Biosciences, Inc. This is a Phase 1 safety and dose escalation study to define the maximum tolerated dose (MTD) and identify the dose limiting toxicities (DLT) following IV administration of GPX-150 once every 3 weeks. Escalating doses starting at the dose of 14 mg/m2 and increasing to the dose of 265 mg/m2 will be administered IV once every 3 weeks for up to 8 cycles of treatment. Patients who have previously received an anthracycline are limited to 4 cycles of treatment. (source: http://clinicaltrials.gov/ct2/show/NCT00710125).
